Cancer

FDA Approves First-of-a-Kind Test for Cancer Gene Profiling

U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what’s driving a patient’s tumor and aiding efforts to match treatments to those flaws. The U.S. Food and Drug Administration approved Foundation Medicine’s test for patients with advanced or widely spread cancers, and

December 12th, 2017|Categories: Cancer, Disease Specific|Tags: , , |

SLU Researchers Discover BRCA Cancer Cells’ Last Defense

In a new paper published in Nature Communications, a team led by Saint Louis University researcher Alessandro Vindigni, Ph.D. shares new information about how BRCA-deficient cancer cells operate, interact with chemotherapy drugs and what may be their last-ditch effort to survive. Researchers hope their findings may lead to improved chemotherapy drugs and shed light on why

November 29th, 2017|Categories: Around The State, Cancer, Disease Specific|Tags: , , , |

New System for Treating Colorectal Cancer Can Lead to Complete Cure

Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate--without any treatment-related toxic effects. The study is reported

November 13th, 2017|Categories: Cancer, Disease Specific|Tags: , |

Gene Circuit Switches on Inside Cancer Cells, Triggers Immune Attack

Researchers at MIT have developed a synthetic gene circuit that triggers the body’s immune system to attack cancers when it detects signs of the disease. The circuit, which will only activate a therapeutic response when it detects two specific cancer markers, is described in a paper published today in the journal Cell. Immunotherapy is widely seen

October 31st, 2017|Categories: Cancer, Disease Specific|Tags: , |

FDA Approves First Gene Therapy for non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta) to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Kite Pharma’s Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy

October 28th, 2017|Categories: Cancer, Disease Specific|Tags: , , |

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells

Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. Evripidis Gavathiotis, Ph.D.“We’re hopeful that

October 20th, 2017|Categories: Cancer, Disease Specific|Tags: , |

Biologists Identify Possible New Strategy for Halting Brain Tumors

MIT biologists have discovered a fundamental mechanism that helps brain tumors called glioblastomas grow aggressively. After blocking this mechanism in mice, the researchers were able to halt tumor growth. The researchers also identified a genetic marker that could be used to predict which patients would most likely benefit from this type of treatment. Glioblastoma is

October 9th, 2017|Categories: Cancer, Disease Specific|Tags: , , |

Chemo-loaded nanoparticles target breast cancer that has spread to bone

Breast cancer that spreads often infiltrates bone, causing fractures and intense pain. In such cases, chemotherapy is ineffective because the environment of the bone protects the tumor, even as the drug has toxic side effects elsewhere in the body. Now, scientists at Washington University School of Medicine in St. Louis have developed a nanoparticle that

New Technology Helps Take Guesswork Out of Prostate Cancer Detection

For 61-year-old marketing director Gene Frazier, ignorance is anything but bliss. Frazier’s father died of complications from prostate cancer at 71, putting his son at an increased risk of developing the disease. Thanks to a new technology used by urologists at University of Missouri Health Care, he knows he’s not leaving his prostate health to